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A need exists for rapid, low-cost, and accurate infectious viral quantification method in the bio-pharmaceutical 
field for the production of vaccines and virus-based therapeutics. Two of the most common and traditionally 
employed methods to quantify infectious viruses are plaque assays and cell culture infectious dose 50 (CCID50); 
both are relatively inexpensive, however they can be time consuming and demonstrate significant variability 
between operators. Here we present a method to quantify infectious viruses using the post-infection granular 
changes within the cell using flow cytometry to create a more rapid and high throughput quantification method. To 
validate this method, a recombinant Vero cell line was infected with a replication-deficient herpes simplex virus 
type 2 mutant and monitored over a 72 hour period for changes in granularity, using flow cytometry. Between 16-
20 hours post infection (hpi), the percentage of the cell population displaying a high degree of granularity can be 
logarithmically correlated to the infectious titer of the viral sample. The granularity-based assay was used to 
estimate the infectious titer of 5 separate virus samples and the results were compared titers obtained through 
plaque assays. It was found that there was a maximum difference of 52.67% in the average titers between assays. 
To further demonstrate this as a universal method, Japanese quail muscle fibroblast cells (QT-35) were infected 
with a highly attenuated canarypox virus and their granularity was tracked. A similar increase in granularity post 
infection was detected, thereby giving credence to the utility of this viral enumeration technique across a potentially 
broad virus-host cell range. Given the high level of correlation between the proposed and traditional methods of 
viral quantification, the use of flow cytometry could aid in process development and optimization by decreasing 


















A 6.00±1.81 30.11% 9.16±4.53 49.42% -52.67% 
B 6.33±4.13 65.35% 8.94±3.00 33.52% -41.32% 
C 6.34±2.20 34.62% 4.13±1.33 32.17% 34.85% 
D 6.28±0.99 15.81% 4.96±1.50 30.23% 21.01% 
E 61.7±7.67 12.43% 90.3±39.1 43.26% -46.45% 
Figure 1- Semilogarithmic plot correlating the percent of 
the population with high granularity to the concentration 
of infective virus (PFU) for 6 separate herpes virus 
samples. The trend line was calibrated using a standard 
sample with a well-defined titer 
Table 1- A comparison of the infectious titers obtained 
from each assay with the variance associated with each 
measurement. The difference between the two assays 
was calculated by: (Mean titer of Granularity-based 
assay – Mean titer of Plaque assay) / (Mean titer of 
Plaque assay) x 100 
